Mechanically responsive drug activation refers to a class of smart therapeutic systems that can sense and respond to changes in the biomechanical microenvironment and become selectively activated. Under abnormal mechanical cues such as elevated blood shear stress, interstitial pressure, or cellular traction forces, these systems undergo controllable structural transitions or surface de-shielding, thereby exposing active targeting ligands or triggering drug release for site-specific therapy.

The core concept is to convert biomechanical signals into programmable activation mechanisms, enabling drugs to remain inert during systemic circulation and become “switched on” only within disease-associated mechanical niches. This strategy significantly improves therapeutic specificity while reducing off-target toxicity to healthy tissues.

Key technological components include the rational design of nanomaterials, engineering of mechano-sensitive chemical bonds, tunable ligand shielding strategies, and multiscale biomechanical modeling. This interdisciplinary field integrates materials science, chemistry, biomechanics, and biomedical engineering.

Mechanically activated drug systems hold strong potential in the treatment of thrombosis, atherosclerosis, tumor microenvironments, and inflammatory diseases, and represent a frontier direction in smart nanomedicine and precision therapeutics.